Table 2 Information on the cervical cancer patients.
From: SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer
No. | Sex | Age | Histopathological type | Differentiation | Lymph node metastasis | FIGO Stage | IHC immunoscore |
|---|---|---|---|---|---|---|---|
1 | Female | 51 | Adenocarcinoma | Low | Yes | IIIC1 | 6 |
2 | Female | 50 | Squamous | Mid | No | IIA | 4 |
3 | Female | 62 | Squamous | Mid | Yes | IIIC1 | 4 |
4 | Female | 52 | Squamous | Mid | No | IB1 | 3 |
5 | Female | 46 | Squamous | Mid | No | IB2 | 3 |
6 | Female | 51 | Squamous | Mid | No | IA2 | 2 |
7 | Female | 51 | Squamous | Mid | No | IIA2 | 4 |
8 | Female | 48 | Squamous | Mid | No | IIA1 | 4 |
9 | Female | 44 | Squamous | Mid to Low | No | IIA2 | 4 |
10 | Female | 54 | Squamous | High | No | IB1 | 2 |
11 | Female | 58 | Squamous | High | No | IB1 | 2 |
12 | Female | 68 | Squamous | Mid | No | IA2 | 2 |
13 | Female | 51 | Squamous | Mid to Low | No | IB1 | 2 |
14 | Female | 59 | Squamous | Mid | No | IIA1 | 4 |
15 | Female | 51 | Squamous | High | No | IB1 | 2 |
16 | Female | 61 | Squamous | Mid to Low | Yes | IIA2 | 4 |
17 | Female | 52 | Adenocarcinoma | Mid | No | IB1 | 2 |
18 | Female | 54 | Squamous | Mid to Low | No | IB1 | 3 |
19 | Female | 72 | Squamous | Mid to Low | Yes | IIA1 | 4 |
20 | Female | 48 | Adenocarcinoma | Mid | No | IA2 | 2 |
21 | Female | 70 | Squamous | Mid | No | IB1 | 2 |
22 | Female | 73 | Adenocarcinoma | Mid to Low | No | II | 4 |
23 | Female | 61 | Squamous | Mid to Low | No | IB2 | 3 |
24 | Female | 64 | Squamous | Mid | No | IIA | 3 |
25 | Female | 54 | Adenosquam | Mid to Low | Yes | IIA1 | 4 |
26 | Female | 56 | Squamous | Mid | Yes | IIIB | 6 |
27 | Female | 36 | Squamous | Mid | No | IIA1 | 3 |
28 | Female | 58 | Squamous | Mid to Low | Yes | IB2 | 3 |
29 | Female | 61 | Squamous | Mid | No | IIA2 | 4 |
30 | Female | 51 | Squamous | Mid | No | IB1 | 2 |
31 | Female | 40 | Squamous | Mid | No | IB3 | 2 |
32 | Female | 80 | Adenocarcinoma | Mid | No | IIA2 | 4 |
33 | Female | 45 | Adenocarcinoma | Mid | No | IIA1 | 4 |
34 | Female | 58 | Squamous | Mid | No | IB3 | 3 |
35 | Female | 53 | Squamous | Mid | No | IIA2 | 4 |
36 | Female | 83 | Squamous | Low | No | IB2 | 4 |
37 | Female | 59 | Squamous | Mid | No | IIA1 | 4 |
38 | Female | 68 | Adenocarcinoma | Mid | No | IB2 | 2 |
39 | Female | 53 | Adenocarcinoma | Mid | No | IB1 | 2 |
40 | Female | 57 | Adenocarcinoma | Mid | Yes | IVB | 6 |
41 | Female | 59 | Squamous | Mid | No | IB3 | 2 |
42 | Female | 33 | Squamous | Mid | No | IB3 | 2 |
43 | Female | 78 | Squamous | Mid | Yes | IIB | 4 |
44 | Female | 77 | Squamous | Mid | No | IB3 | 3 |
45 | Female | 75 | Adenocarcinoma | Mid | No | IB1 | 2 |
46 | Female | 45 | Squamous | Mid to Low | Yes | IIIC1 | 4 |
47 | Female | 51 | Squamous | Mid | No | IIA2 | 2 |
48 | Female | 71 | Squamous | Mid | No | IIA | 2 |
49 | Female | 72 | Adenocarcinoma | Low | Yes | IIIC1 | 9 |
50 | Female | 69 | Squamous | Mid | No | IB2 | 3 |
51 | Female | 47 | Squamous | Mid to Low | Yes | IIA2 | 4 |
52 | Female | 48 | Squamous | Low | Yes | IIIC2 | 4 |
53 | Female | 53 | Adenocarcinoma | Mid | Yes | IB2 | 2 |
54 | Female | 62 | Squamous | Mid to Low | Yes | IIA2 | 4 |
55 | Female | 49 | Adenocarcinoma | Low | No | IB2 | 4 |
56 | Female | 59 | Adenocarcinoma | Mid to Low | No | IIA2 | 4 |
57 | Female | 71 | Squamous | Low | No | IIA1 | 4 |
58 | Female | 54 | Adenocarcinoma | Low | No | IB2 | 3 |
59 | Female | 39 | Squamous | Mid | Yes | IIA1 | 4 |
60 | Female | 53 | Squamous | Mid | No | IB2 | 2 |
61 | Female | 50 | Undifferentiated | Low | No | IB1 | 3 |
62 | Female | 37 | Adenocarcinoma | Mid | Yes | IB3 | 9 |
63 | Female | 56 | Adenosquam | Mid to Low | Yes | IIA2 | 6 |
64 | Female | 76 | Squamous | Low | No | IB | 4 |
65 | Female | 73 | Squamous | Mid | No | IIA1 | 3 |
66 | Female | 67 | Squamous | Mid | No | IIA2 | 4 |
67 | Female | 72 | Squamous | Low | Yes | IIA | 4 |
